Thrombotic complications are frequent in patients with Essential Thrombocythaemia (ET) and Polycythaemia Vera (PV). A raised haematocrit and thrombocytosis have been implicated in the pathogenesis but events still occur on treatment. We hypothesized that there was a role for other prothrombotic and inflammatory pathways in the aetiology of thrombosis in MPD, and so assessed these parameters in 101 patients and 51 controls. Assays and results are listed in table below. Standard methods of thromboelastography, flow cytometry, RVVT assays and ELISAs were used. 72 ET and 29 PV patients were included: median age 58 years (range17–89), disease duration 84 months (range 2–384) and platelet counts 473 × 109/l (range 207–1780). 59 (58%) patients had the JAK2 V617F mutation. 51 (50%) had thrombosis with 23 patients developing the events post-diagnosis. 82 (81%) patients were receiving anti-platelet agents and 76 (75%) cytoreductive therapy. Comparison with clinical features revealed V617F positive patients to be older with significantly higher haemoglobin and PCV and greater levels of E-selectin and C3a, contrary to the higher platelet activation recently shown by Arellano-Rodrigo (2006). The only parameters that correlated with previous thrombosis were older age, longer disease duration and increased CD63 levels +/− ADP stimulation. Cytoreductive therapy was associated with lower levels of VEGF (p=0.01) but no other parameters. In conclusion, assessment of haemostatic, endothelial, complement, angiogenic and inflammatory markers shows evidence of increased activation in patients with MPD. Of these parameters, only the angiogenic marker was reduced by cytoreductive therapy and none appear to be associated with the risk of thrombosis.

Median values of prothrombotic and inflammatory parameters

ParametersTestUnitsPatientsControlsp-value
NS=non-significant, PMP=platelet-microparticles, ADP=adenosine diphosphate, PMA= platelet-monocyte aggregates, PGA=platelet-granulocyte aggregates 
Thromboelastograph R-time secs   NS 
 K-time secs 137.5 160 0.002 
 α- angle degrees 58.7 52.8 <0.0001 
 MA mm 64.1 59 <0.0001 
Functional PMP 0.2μm-filterd plasma  2.35 2.6 <0.0001 
 0.1μm-filtered plasma  2.42 2.8 <0.0001 
Quantitative PMP PMP % 6.41 4.58 <0.0001 
 Annexin V+ PMP % 0.19 0.15 0.002 
Platelet activation Annexin V+ plts % 2.63 2.07 0.004 
 CD62p % 1.00 0.52 <0.0001 
 CD62p +ADP %   NS 
 CD63 % 3.32 2.12 0.01 
 CD63 +ADP % 22.2 16.1 0.004 
 soluble p-selectin mg/ml 172.5 74.7 <0.0001 
Platelet-leucocyte aggregates PMA % 12.20 5.94 <0.0001 
 PGA % 4.56 3.77 <0.0001 
Monocyte-tissue factor 0hr % 0.6 0.24 <0.0001 
 1hr % 1.32 0.62 <0.0001 
 4hr %   NS 
Endothelial activation soluble ICAM-1 ng/ml 235.9 194.3 0.013 
 soluble E-selectin ng/ml   NS 
Complement activation plasma C3a ng/ml 113.4 94.2 0.001 
Angiogenesis soluble VEGF pg/ml 670 196.2 <0.0001 
Inflammatory markers serum IL-8 pg/ml 12.9 11.1 <0.0001 
 serum CRP, IL-6    NS 
Haemostasis markers plasma PF 1+2 nmol/l 0.7 0.6 0.027 
 plasma PAI-1 ng/ml 27.2 21.1 0.001 
 D-Dimers, tPA, TAFI    NS 
ParametersTestUnitsPatientsControlsp-value
NS=non-significant, PMP=platelet-microparticles, ADP=adenosine diphosphate, PMA= platelet-monocyte aggregates, PGA=platelet-granulocyte aggregates 
Thromboelastograph R-time secs   NS 
 K-time secs 137.5 160 0.002 
 α- angle degrees 58.7 52.8 <0.0001 
 MA mm 64.1 59 <0.0001 
Functional PMP 0.2μm-filterd plasma  2.35 2.6 <0.0001 
 0.1μm-filtered plasma  2.42 2.8 <0.0001 
Quantitative PMP PMP % 6.41 4.58 <0.0001 
 Annexin V+ PMP % 0.19 0.15 0.002 
Platelet activation Annexin V+ plts % 2.63 2.07 0.004 
 CD62p % 1.00 0.52 <0.0001 
 CD62p +ADP %   NS 
 CD63 % 3.32 2.12 0.01 
 CD63 +ADP % 22.2 16.1 0.004 
 soluble p-selectin mg/ml 172.5 74.7 <0.0001 
Platelet-leucocyte aggregates PMA % 12.20 5.94 <0.0001 
 PGA % 4.56 3.77 <0.0001 
Monocyte-tissue factor 0hr % 0.6 0.24 <0.0001 
 1hr % 1.32 0.62 <0.0001 
 4hr %   NS 
Endothelial activation soluble ICAM-1 ng/ml 235.9 194.3 0.013 
 soluble E-selectin ng/ml   NS 
Complement activation plasma C3a ng/ml 113.4 94.2 0.001 
Angiogenesis soluble VEGF pg/ml 670 196.2 <0.0001 
Inflammatory markers serum IL-8 pg/ml 12.9 11.1 <0.0001 
 serum CRP, IL-6    NS 
Haemostasis markers plasma PF 1+2 nmol/l 0.7 0.6 0.027 
 plasma PAI-1 ng/ml 27.2 21.1 0.001 
 D-Dimers, tPA, TAFI    NS 
View Large

Topics:
cytoreductive therapy, inflammatory markers, myeloproliferative disease, thrombosis, cd63 antigen, p-selectin, annexins, e-selectin, illness length, thrombelastography

Disclosures: Claire Harrison- Shire Pharmaceuticals.; Betty Cheung - receiving Educational Grant from Shire Pharmaceuticals.; Betty Cheung, Deepti Radia and Claire Harrison- Shire Pharmaceuticals.

Author notes

*

Corresponding author

2006, The American Society of Hematology
2006
Sign in via your Institution